New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.

[1]  A. Modi,et al.  Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR <30 ml/min , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[2]  R. Chung,et al.  Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents , 2016, Hepatology.

[3]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[4]  K. Reddy,et al.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. , 2015, The New England journal of medicine.

[5]  T. Berg,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.

[6]  X. Forns,et al.  Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV‐decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list , 2015, Transplant international : official journal of the European Society for Organ Transplantation.

[7]  E. Lawitz,et al.  Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C , 2015, Journal of viral hepatitis.

[8]  T. Hassanein,et al.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study , 2015, The Lancet.

[9]  S. Dutta,et al.  Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy , 2015, Clinical Pharmacokinetics.

[10]  F. Carrat,et al.  Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study. , 2015, Clinics and research in hepatology and gastroenterology.

[11]  Hernandez María,et al.  Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. , 2015 .

[12]  R. Chung,et al.  Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency , 2015, Infectious diseases.

[13]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[14]  P. Messa,et al.  Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis , 2015, Digestive Diseases and Sciences.

[15]  L. Rostaing,et al.  Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates , 2015, Journal of transplantation.

[16]  B. Baysal,et al.  Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients , 2015, Infectious diseases.

[17]  M. Sayan,et al.  A case report: antiviral triple therapy with telaprevir in a haemodialysed HCV patient in Turkey. , 2015, Acta clinica Belgica.

[18]  J. Glenn,et al.  Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[19]  R. Chung,et al.  LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target , 2015 .

[20]  K. Reddy,et al.  LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study , 2015 .

[21]  C. Levy,et al.  Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1 , 2014 .

[22]  P. Messa,et al.  Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta‐analysis of clinical studies , 2014, Journal of viral hepatitis.

[23]  D. Burger,et al.  Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[24]  T. Berg,et al.  Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis , 2014, Alimentary pharmacology & therapeutics.

[25]  V. Papastergiou,et al.  Letter: response‐guided treatment of hepatitis C virus genotype 5 may be feasible , 2014, Alimentary pharmacology & therapeutics.

[26]  P. Messa,et al.  Meta‐analysis of observational studies: hepatitis C and survival after renal transplant , 2014, Journal of viral hepatitis.

[27]  Ding‐Shinn Chen,et al.  Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial , 2014, Gut.

[28]  吳俊穎,et al.  Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients , 2014 .

[29]  Ding‐Shinn Chen,et al.  Pegylated Interferon-α2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis , 2013, Annals of Internal Medicine.

[30]  M. Jadoul,et al.  Hepatitis C Infection Is Very Rarely Treated among Hemodialysis Patients , 2013, American Journal of Nephrology.

[31]  P. Messa,et al.  Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  J. Dumortier,et al.  Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[33]  P. Messa,et al.  Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? , 2012, Journal of viral hepatitis.

[34]  D. Dieterich,et al.  A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. , 2010, Gastroenterology.

[35]  A. Macleod.  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. , 2008, Kidney international. Supplement.

[36]  F. Schena,et al.  The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. , 2007, Journal of hepatology.

[37]  A. Craxì,et al.  Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. , 2016, Gastroenterology.

[38]  E. Schiff,et al.  Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. , 2015, Journal of hepatology.

[39]  P. Galle,et al.  Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation. , 2014, Digestive and Liver Disease.